This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
GSK has entered a strategic partnership with Wave LifeSciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.
CAH is a group of rare genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone and androgens. The most common form of CAH, 21-hydroxylase deficiency, disrupts hormone production, leading to cortisol deficiency and an overproduction of androgens.
The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance lifesciences.
As we step into 2024, the lifesciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables.
Another unique challenge in psychiatry trials is the placebo response, which is notably high in mental health research. Each patients experience with mental health conditions is influenced by unique genetic, psychological and environmental factors.
One of the more intriguing developments in cancer research in recent years is the growing understanding of clonal hematopoiesis, a phenomenon where blood cells expand from a single clone due to genetic mutations. Clonal hematopoiesis increases in prevalence with age and can precede hematologic malignancies.
Lifescience workers are one of the most common areas of work that could not eliminate all visits to the office or lab during the COVID-19 pandemic. Some scientists and researchers have been visiting their workplaces during the pandemic. So, what will work look like in the lifesciences as we emerge from the pandemic?
It leverages various patient-specific factors, including genetics, age, weight, organ function and even lifestyle, to determine the most appropriate dosage for each individual. Her career spans pediatric clinical pharmacy, clinical research and pharmacogenomics with leadership roles at University of Chicago Medical Center and PipelineRx.
Medical and lifescienceresearchers will benefit from the most comprehensive atlas yet of genetic data on zebrafish, newly published research suggests. The atlas will help researchers to better study conditions from various types of cancer (e.g. skin cancer), heart disease, and neurodegeneration.
CF is a progressive genetic disease caused by defective CFTR proteins, which are crucial for regulating salt and water movement in cells. Vertex remains committed to advancing CF research, with plans to expand the impact of their CFTR modulators and explore new genetic mutations.
Approximately 80% of these diseases have a genetic basis , and many manifest in childhood , often with significant challenges in achieving a timely and accurate diagnosis. This variability not only poses challenges for diagnosis but also stresses the need for targeted research and innovative therapeutic approaches.
The company plans to use these funds to advance its groundbreaking research in small molecule precision medicines, targeting renal, cardiovascular and metabolic diseases, including obesity. For complex diseases like chronic kidney disease (CKD), where genetics play a significant role, such a platform holds promise.
To learn more about new Parkinson’s disease research, Ayesha discussed a new study by researchers at Rush University Medical Center that shows statins may help decrease the risk of parkinsonism in older adults. Genedrive’s Genetic Test Can Prevent Hearing Loss in Babies Through Personalized Treatment.
That investment, equal to the National Institutes of Health’s annual spending on medical research, would seem like great news for a world waiting for help with a pandemic. A group of early-stage lifescience investors and biotech CEOs joined together with a prominent patient advocate to speak out against H.R.3,
Forge Biologics and global lifesciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration.
Lawreen is a seasoned biotech and lifescience professional with over 25 years of experience. She began her career as a research scientist, working for more than eight years in this role before transitioning into product management and marketing. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
Ayesha spoke about how the Rare Disease Day campaign helps increase awareness about rare diseases, promotes research and development, supports advocacy for policies supporting patients and their families and brings together a global rare disease community. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
This initiative is particularly impactful for rare diseases and genetic disorders, where traditional endpoints may be infeasible. Programs like the Rare Disease Endpoint Advancement Pilot encourage collaboration with the FDA to establish novel surrogate endpoints.
For Rare Disease Day, RBW Consulting’s Emma Thorp discusses why the consultancy is taking revenue earned from its rare disease clients and using it to fund research into the mental health impact of a rare disease diagnosis. Issues like this, and experiences like mine, are why RBW is funding a partnership with Rare Disease Research Partners.
The Israeli Society of Gene and Cell Therapy (ISGCT) is hosting its upcoming annual meeting in-person this year to encourage networking and the sharing of information about genetic and cellular therapies. The aim of the ISGCT is to foster and maintain strong scientific communities in this field of research.
Solid Biosciences has entered a strategic research collaboration with Phlox Therapeutics to expedite the development of new therapies for rare cardiac diseases. Under the research partnership deal, the companies will develop new precision genetic medicines for a severe form of genetic dilated cardiomyopathy (DCM).
Technological advancements are revolutionizing cancer research and therapies. By editing these genes, researchers can effectively neutralize their cancer-promoting effects. By tailoring treatments based on an individual’s genetic makeup, it may allow for more effective and targeted therapies.
For several decades, researchers have been investigating the role of ketamine in treating depression. PharmaTher also has an agreement in place with Case Western Reserve University to develop ketamine as a treatment for Rett syndrome, a rare genetic neurological disorder. Depression research spurs efforts for other conditions.
The editorial team discussed the encouraging growth seen in recent years in rare disease clinical research in the lifescience industries, providing hope for improved diagnosis, care and treatments for patients with rare diseases. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
Generation of strong research dataset cohorts must begin with high-quality clinical samples. Moreover, biobanks are no longer passive biorepositories for accrual of samples and serve a more utilitarian function in identifying and coordinating specific research cohorts for longitudinal and prospective studies.
This therapy, the first of its kind to be administered directly into the brain, addresses a rare genetic disorder that severely affects motor function and dopamine production.
In this episode, Ayesha shared new research about how scientists at the Francis Crick Institute and University College London have found a mechanism of action to explain how air pollution may cause lung cancer in non-smokers. can act on existing genetic mutations to trigger inflammation and the development of cancer.
Martin Mendoza, PhD, director of health equity and health science policy for the All of Us Research Program at the National Institutes of Health (NIH), tells pharmaphorum about the programme and how it will accelerate research for the benefit of all patients. Gathering data.
Diversity, equity and inclusion (DEI) have become important elements in the landscape of clinical research. Xtalks spoke with Stacy Weil, DHI, Senior Vice President, Business Operations and Patient Centricity, Premier Research, to gain insights into incorporating DEI practices and plans in clinical research.
Eli Lilly shared new Phase II trial data showing that its experimental siRNA therapy, lepodisiran, leads to reductions in levels of lipoprotein(a) (Lp(a)) a genetically inherited risk factor for heart disease in adults with elevated levels of the marker. High Lp(a) levels can double or even triple the risk of a heart attack.
Drug resistance in DEEs often stems from genetic and molecular factors unique to each syndrome, limiting standard treatments’ effectiveness. This extension aims to provide insights into long-term safety, addressing a common gap in epilepsy research. She noted that DEEp OCEAN is a step towards inclusivity in clinical research.
There are over 10,000 rare diseases affecting an estimated 300 million people worldwide where 80% are genetic , 95% lack approved treatments and nearly half begin in childhood. Cross-border enrollment captures a wider range of genetic backgrounds, environmental influences, and cultural perspectives.
points as assessed by the Medical Research Council (MRC) sum score. Severe GBS patients treated with a single dose of imlifidase (0.25 By the first week, 37 percent of patients were able to walk independently. The mean improvement in muscle strength was 10.7 By eight weeks, 67 percent of patients were able to walk independently, 40.7
In clinical research, this includes designing trials that elevate the patient voice, reduce barriers to participation, and represent the diverse populations who will ultimately use these medical products. This distrust is further compounded by a lack of visible accountability and representation in the research process.
Originally discovered in bacteria as a defense mechanism against pathogens, CRISP/Cas9 has made it possible to make exquisitely detailed and precise alterations to DNA sequences on demand, and as a tool for molecular biology has already transformed research into diseases and drug discovery. What started as a curiosity?driven,
Researchers at Nano LifeScience Institute (WPI-NanoLSI), Kanazawa University, have discovered how a protein called lamin A helps repair the protective barrier around a cell's DNA.
Some research suggests that optimized microfluidic devices can isolate rare CTCs with recovery rates exceeding those of conventional methods sometimes reaching over 90% under ideal conditions.
A new study published in the journal Science Advances has reported the identification of 50 previously unknown genes involved in the determination of human eye color variation. The study was led by a team of researchers at King’s College London and Erasmus University Medical Center Rotterdam. The researchers say that collectively, 53.2
As many strive to bring about transformation in healthcare, Angelini Ventures takes a new approach to investments in digital health and lifesciences companies that drive healthcare innovation and improve patient experiences. It aims to shape companies in the digital healthcare, connected medical devices, and lifesciences spaces.
The study , published in the journal Science of the Total Environment , offers the first lines of evidence for how climate change could have played a direct role in the appearance of the COVID-19 pandemic-causing virus. The research also highlights the potential mechanism involved in the phenomenon. Comparative Analysis and Mapping.
The FNIH will focus on advancing clinical trials for the eight diseases through gene therapy research partnerships with the goal of accelerating the path of new therapies to clinical trials. Of the more than 10,000 rare diseases, more than 80 percent are caused by genetic defects.
Other issues include medical systems that can often be dismissive of women’s health concerns or experiences, and historically less research on women’s health, which together, can lead to late diagnoses or misdiagnoses. Through this, researchers can pinpoint breast cancer cell types and their phenotypic states.
Do you possess laboratory skills, an analytical mindset and a penchant for research? A clinical scientist conducts research to help prevent illness and develops techniques to support patient diagnosis and treatment. They will often find themselves working in a healthcare or pharmaceutical field that supports human health research.
One group excelling in this space is the Genetic Alliance. Their work ranges from developing new services in partnership with the National Health Service (NHS) to working with the All Party Parliamentary Group on Rare, Genetic and Undiagnosed Conditions, and the Department of Health on the UK Strategy for Rare Diseases.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content